T
TRIB

Transce3nd’s Trinity Biotech TRIB Stock Holding History

Transce3nd’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$2 – 1066
2025
Q2 		$2 Hold
3
– – ﹤0.01% 1213
2025
Q1 		$2 Hold
3
– – ﹤0.01% 1184
2024
Q4 		$3 Buy
+3
New +$4 ﹤0.01% 1563

Other funds holding TRIB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return

Transce3nd's TRIB Position: Q3 2025 in Review

Transce3nd sold out of Trinity Biotech (TRIB) in Q3 2025, closing a stake of 3 shares — an estimated $2 sold.

Transce3nd first reported a position in TRIB in Q4 2024 and held it in 3 quarters. The position peaked at $3 in Q4 2024. 28 funds tracked by Wall St. Rank hold TRIB as of Q3 2025.

  • Transce3nd reported no remaining Trinity Biotech position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 3 Trinity Biotech shares in Q3 2025, an estimated $2.
  • Transce3nd first reported a position in Trinity Biotech in Q4 2024 and held it in 3 quarters.
  • Transce3nd's Trinity Biotech position peaked at $3 in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.